tipifarnib has been researched along with Astrocytoma, Grade IV in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrey, LE; Aldape, K; Chang, S; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Ebiana, VA; Gilbert, M; Kuhn, J; Levin, VA; Lieberman, F; Mehta, MP; Nghiemphu, PL; Prados, M; Robins, HI; Wen, P; Wright, JJ; Yung, WKA | 1 |
| Benouaich-Amiel, A; Cohen-Jonathan Moyal, E; De Porre, P; Delisle, MB; Ducassou, A; Favre, G; Filleron, T; Ken, S; Laprie, A; Lubrano, V; Poublanc, M; Sol, JC; Toulas, C; Uro-Coste, E; Verrelle, P | 1 |
| Berry, I; Catalaa, I; Celsis, P; Cohen-Jonathan Moyal, E; Deviers, A; Filleron, T; Ken, S; Laprie, A; Laruelo, A; Lubrano, V; Mogicato, G; Rowland, B | 1 |
| Berry, I; Catalaa, I; Celsis, P; Deviers, A; Filleron, T; Ken, S; Khalifa, J; Laprie, A; Lotterie, JA; Lubrano, V; Moyal, EC; Péran, P | 1 |
| Desideri, S; Fisher, J; Grossman, S; Lesser, G; Lustig, R; Mikkelsen, T; Wright, J; Ye, X | 1 |
| Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY | 1 |
| Cohen-Jonathan, E; Delmas, C; End, D; Favre, G; Rochaix, P; Toulas, C | 1 |
| Cacalano, NA; Iwamoto, KS; Liao, YP; McBride, WH; Mischel, PS; Wang, CC | 1 |
| Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; DeAngelis, LM; Fink, KL; Gilbert, MR; Groves, MD; Junck, L; Kuhn, J; Lamborn, KR; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Schiff, D; Wen, PY; Wright, J; Yung, WK | 1 |
| Alaux, B; Berchery, D; Bousquet, P; Catalaa, I; Dalenc, F; De Porre, P; Delannes, M; Laprie, A; Moyal, EC; Poublanc, M; Sabatier, J; Toulas, C | 1 |
8 trial(s) available for tipifarnib and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Sorafenib; Treatment Outcome | 2018 |
αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fibroblast Growth Factor 2; Focal Adhesion Kinase 1; Glioblastoma; Humans; Integrin alphaVbeta3; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinolones; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vitronectin; Treatment Outcome | 2013 |
Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Choline; Creatine; Female; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Radiotherapy, Conformal; Sensitivity and Specificity | 2014 |
Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cerebrovascular Circulation; Contrast Media; Female; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Quinolones; Radiotherapy; Survival Analysis; Treatment Outcome | 2015 |
Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Neurosurgical Procedures; Quinolones; Radiotherapy | 2008 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Quinolones; Temozolomide | 2011 |
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Induction; Epilepsy; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Quinolones; Treatment Outcome | 2006 |
Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal | 2007 |
2 other study(ies) available for tipifarnib and Astrocytoma, Grade IV
| Article | Year |
|---|---|
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Hypoxia; Enzyme Inhibitors; Farnesyltranstransferase; Glioblastoma; Glioma; Humans; Immunoenzyme Techniques; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Quinolones; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway.
Topics: Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Enzyme Inhibitors; Farnesyltranstransferase; Glioblastoma; HSP40 Heat-Shock Proteins; Humans; Quinolones; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2006 |